Breast Cancer

Initial management requires integration of clinical stage, tumor histology and grade, ER/PR and HER2 status, and patient factors. These variables determine operability, the role and timing of systemic therapy, radiation planning, and whether neoadjuvant treatment can guide adjuvant escalation. ESMO+1ESMOESMO Clinical Practice Guideline: Early Breast CancerASCONew ASCO Guideline Offers Recommendations for Neoadjuvant Breast Cancer Treatment

For early breast cancer, treatment sequencing should be deliberate rather than reflexive. ASCO recommends using histology, grade, stage, and ER, PR, and HER2 expression to decide on neoadjuvant chemotherapy. Neoadjuvant systemic therapy is particularly useful in high-risk HER2-positive or triple-negative disease when residual disease would change postoperative systemic treatment. ASCOASCONew ASCO Guideline Offers Recommendations for Neoadjuvant Breast Cancer Treatment

For high-risk HER2-positive or triple-negative breast cancer, neoadjuvant systemic therapy is recommended when residual disease would guide postoperative treatment. In this setting, failure to achieve pathologic complete response identifies a group with worse prognosis and an opportunity for adjuvant treatment modification. ASCOASCONew ASCO Guideline Offers Recommendations for Neoadjuvant Breast Cancer Treatment

For clinically node-positive and/or at least T1c triple-negative breast cancer, ASCO recommends an anthracycline- and taxane-containing neoadjuvant regimen. Neoadjuvant therapy should not be routinely offered outside a clinical trial for cT1a or cT1bN0 triple-negative tumors. ASCOASCONew ASCO Guideline Offers Recommendations for Neoadjuvant Breast Cancer Treatment

In postmenopausal patients with hormone receptor-positive, HER2-negative disease, neoadjuvant endocrine therapy with an aromatase inhibitor is an endorsed option. In contrast, preoperative chemotherapy in this subgroup should be reserved for cases in which the chemotherapy decision does not require tumor-specific genomic testing or final surgical pathology. ASCOASCONew ASCO Guideline Offers Recommendations for Neoadjuvant Breast Cancer Treatment

Guidelines consistently support at least 5 years of adjuvant endocrine therapy in hormone receptor-positive early breast cancer. The principal strategies described across guidelines are tamoxifen for premenopausal patients and aromatase inhibitor therapy, either initially or sequentially after tamoxifen, for postmenopausal patients. NatureNatureSystematic review of clinical practice guidelines for long-term breast cancer survivorship: assessment of quality and evidence-based recommendations | British Journal of Cancer

Extension should be individualized. Some guidelines support tamoxifen for up to 10 years in premenopausal patients or those unable to tolerate aromatase inhibitors, and extension of aromatase inhibitor therapy up to a maximum of 10 years in high-risk postmenopausal patients. NatureNatureSystematic review of clinical practice guidelines for long-term breast cancer survivorship: assessment of quality and evidence-based recommendations | British Journal of Cancer However, other guidelines note limited incremental benefit beyond 7 to 8 years, underscoring the need to weigh nodal status, tumor size and grade, tolerability, competing risk, and patient preference. NatureNatureSystematic review of clinical practice guidelines for long-term breast cancer survivorship: assessment of quality and evidence-based recommendations | British Journal of Cancer

This decision is particularly relevant because hormone receptor-positive tumors may recur decades after diagnosis, whereas hormone receptor-negative tumors have a very low recurrence rate beyond 8 years. NatureNatureSystematic review of clinical practice guidelines for long-term breast cancer survivorship: assessment of quality and evidence-based recommendations | British Journal of Cancer

The American Cancer Society/ASCO survivorship guideline recommends regular cancer-related history and physical examination and screening for a new primary breast cancer. It does not support routine laboratory tests or imaging studies to search for recurrence in asymptomatic survivors. PubMedPubMedAmerican Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline - PubMed

Long-term guideline synthesis identifies annual clinical follow-up beginning in the sixth year after primary treatment as a common recommendation. Annual mammography beginning in the fifth year is also broadly recommended, with individualization by age, relapse risk, tumor characteristics, and whether breast-conserving surgery or mastectomy was performed. NatureNatureSystematic review of clinical practice guidelines for long-term breast cancer survivorship: assessment of quality and evidence-based recommendations | British Journal of Cancer

Order laboratory tests or imaging other than breast-directed imaging when symptoms, examination, or other findings raise clinical suspicion for recurrence or metastasis, rather than as scheduled surveillance in asymptomatic patients. Nature+1NatureSystematic review of clinical practice guidelines for long-term breast cancer survivorship: assessment of quality and evidence-based recommendations | British Journal of CancerPubMedAmerican Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline - PubMed

ASCO concludes that gene-expression testing, primary surgery, adjuvant chemotherapy, radiation therapy, and chemotherapy for advanced disease should generally follow the same approach used for women. ASCOASCOManagement of Male Breast Cancer: ASCO Guideline Male breast cancer nevertheless requires specific attention to endocrine therapy, germline testing, breast imaging after treatment, and treatment-related sexual and thrombotic toxicity. ASCOASCOManagement of Male Breast Cancer: ASCO Guideline

For hormone receptor-positive early-stage male breast cancer, offer tamoxifen for an initial duration of 5 years. Men who tolerate tamoxifen and remain at high recurrence risk after 5 years may be offered another 5 years. When tamoxifen is contraindicated, an aromatase inhibitor should be paired with a gonadotropin-releasing hormone agonist or antagonist rather than used alone. ASCOASCOManagement of Male Breast Cancer: ASCO Guideline

For metastatic hormone receptor-positive, HER2-negative disease, endocrine therapy is preferred first-line treatment unless there is visceral crisis or rapidly progressive disease. Options include tamoxifen, aromatase inhibitor plus gonadotropin-releasing hormone therapy, and fulvestrant; CDK4/6 inhibitors may be used as in women. ASCOASCOManagement of Male Breast Cancer: ASCO Guideline

Contemporary metastatic breast cancer guidelines organize treatment around luminal, HER2-positive, and triple-negative disease, as well as diagnostic work-up, staging, molecular assessment, site-specific metastatic management, and survivorship. ESMO+1ESMOESMO Clinical Practice Guideline: Metastatic Breast CancerESMOESMO Living Guideline: ​Metastatic Breast Cancer Biomarker status drives endocrine, HER2-targeted, immunotherapy, and other targeted treatment choices. ASCO+1ASCOManagement of Male Breast Cancer: ASCO GuidelineESMOESMO Living Guideline: ​Metastatic Breast Cancer

For men with advanced disease, ASCO supports use of targeted treatment guided by HER2, PD-L1, PIK3CA, and germline BRCA status using the same indications and combinations offered to women, while acknowledging that the male-specific evidence base is limited. ASCOASCOManagement of Male Breast Cancer: ASCO Guideline

Patients with inflammatory breast cancer without distant metastasis require prompt multimodality care. In a U.S. patterns-of-care cohort, only 25.8% received guideline-concordant treatment; prompt referral for neoadjuvant chemotherapy and postoperative radiation was emphasized. CDC+1CDCInfluence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer - PubMedCDCCDC Stacks